Analyzing Charles River Laboratories International (NYSE:CRL) & Q Biomed (OTCMKTS:QBIO)

Q Biomed (OTCMKTS:QBIO) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares Q Biomed and Charles River Laboratories International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
Charles River Laboratories International	-2.07%	15.78%	7.02%

Insider and Institutional Ownership

98.9% of Charles River Laboratories International shares are owned by institutional investors. 28.2% of Q Biomed shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Q Biomed and Charles River Laboratories International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
Charles River Laboratories International	1	5	11	1	2.67

Charles River Laboratories International has a consensus price target of $195.93, suggesting a potential downside of 8.82%. Given Q Biomed’s higher possible upside, equities research analysts plainly believe Q Biomed is more favorable than Charles River Laboratories International.

Valuation and Earnings

This table compares Q Biomed and Charles River Laboratories International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	$0.08	N/A
Charles River Laboratories International	$4.02 billion	2.63	$22.20 million	($1.56)	-137.75

Charles River Laboratories International has higher revenue and earnings than Q Biomed. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Q Biomed has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Summary

Charles River Laboratories International beats Q Biomed on 7 of the 12 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.